Fariha Jamal1. 1. is an Assistant Professor, Department of Neurology, Baylor College of Medicine and an Assistant Clinical Director at the Parkinson's Disease Research Education and Clinical Center, Michael E. DeBakey VA Medical Center in Houston, Texas.
Abstract
BACKGROUND: Parkinson disease (PD) is a progressive neurodegenerative disorder. Pathologic diagnosis of PD relies on loss of dopamine neurons in the substantia nigra and accumulation of the abnormal protein α-synuclein in the form of Lewy bodies and Lewy neurites. Alteration in aggregation properties of this protein is believed to play a central role in the pathogenesis of PD. OBSERVATIONS: Huge interest has developed in antibody-based therapies for PD. Several studies have tested immunotherapies in PD animal models with the aim of targeting α-synuclein. Immunotherapies can be instituted in 2 ways: active immunization in which the immune system is stimulated to produce antibodies against α-synuclein or passive immunization in which antibodies against α-synuclein are directly administered. CONCLUSIONS: Immunotherapy against α-synuclein has provided a new therapeutic avenue in neuroprotection. Results from the first human clinical trial are promising, but despite these results, more work is needed to clarify the role of α-synuclein in the pathogenesis of PD in humans.
BACKGROUND: Parkinson disease (PD) is a progressive neurodegenerative disorder. Pathologic diagnosis of PD relies on loss of dopamine neurons in the substantia nigra and accumulation of the abnormal protein α-synuclein in the form of Lewy bodies and Lewy neurites. Alteration in aggregation properties of this protein is believed to play a central role in the pathogenesis of PD. OBSERVATIONS: Huge interest has developed in antibody-based therapies for PD. Several studies have tested immunotherapies in PD animal models with the aim of targeting α-synuclein. Immunotherapies can be instituted in 2 ways: active immunization in which the immune system is stimulated to produce antibodies against α-synuclein or passive immunization in which antibodies against α-synuclein are directly administered. CONCLUSIONS: Immunotherapy against α-synuclein has provided a new therapeutic avenue in neuroprotection. Results from the first human clinical trial are promising, but despite these results, more work is needed to clarify the role of α-synuclein in the pathogenesis of PD in humans.
Authors: Bruno Fauvet; Martial K Mbefo; Mohamed-Bilal Fares; Carole Desobry; Sarah Michael; Mustafa T Ardah; Elpida Tsika; Philippe Coune; Michel Prudent; Niels Lion; David Eliezer; Darren J Moore; Bernard Schneider; Patrick Aebischer; Omar M El-Agnaf; Eliezer Masliah; Hilal A Lashuel Journal: J Biol Chem Date: 2012-02-07 Impact factor: 5.157
Authors: Markus Mandler; Elvira Valera; Edward Rockenstein; Harald Weninger; Christina Patrick; Anthony Adame; Radmila Santic; Stefanie Meindl; Benjamin Vigl; Oskar Smrzka; Achim Schneeberger; Frank Mattner; Eliezer Masliah Journal: Acta Neuropathol Date: 2014-02-14 Impact factor: 17.088
Authors: Martí Colom-Cadena; Jordi Pegueroles; Abigail G Herrmann; Christopher M Henstridge; Laia Muñoz; Marta Querol-Vilaseca; Carla San Martín-Paniello; Joan Luque-Cabecerans; Jordi Clarimon; Olivia Belbin; Raúl Núñez-Llaves; Rafael Blesa; Colin Smith; Chris-Anne McKenzie; Matthew P Frosch; Allyson Roe; Juan Fortea; Jordi Andilla; Pablo Loza-Alvarez; Ellen Gelpi; Bradley T Hyman; Tara L Spires-Jones; Alberto Lleó Journal: Brain Date: 2017-12-01 Impact factor: 13.501
Authors: Taye H Hamza; Cyrus P Zabetian; Albert Tenesa; Alain Laederach; Jennifer Montimurro; Dora Yearout; Denise M Kay; Kimberly F Doheny; Justin Paschall; Elizabeth Pugh; Victoria I Kusel; Randall Collura; John Roberts; Alida Griffith; Ali Samii; William K Scott; John Nutt; Stewart A Factor; Haydeh Payami Journal: Nat Genet Date: 2010-08-15 Impact factor: 38.330
Authors: Jacqueline Burré; Sandro Vivona; Jiajie Diao; Manu Sharma; Axel T Brunger; Thomas C Südhof Journal: Nature Date: 2013-06-13 Impact factor: 49.962